Please assess the completion status of the following clinical trial:

Trial Title: Trastuzumab Combined With Chemotherapy or Endocrine Therapy to Treat Metastatic Luminal B2 Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18 years or older.~2. Patients with an Eastern Cooperative Oncology Group (ECOG) score of 0 or 1.~3. Histologically confirmed metastatic or local recurrence of breast cancer.~4. ER positive and/or progesterone receptor (PR) positive, HER-2+ defined as immuno-histochemistry3+ staining or FISH+.~5. Prior adjuvant Trastuzumab therapy is permitted, but disease-free interval (DFI) must be more than 12 months.~6. Patients must have measurable or evaluable disease.~7. Adequate bone marrow reserve with neutrophils \> 1000 and platelets \> 100,000.~8. Adequate renal function with serum creatinine \< 2.0.~9. Adequate hepatic reserve with serum bilirubin \< 2.0, alanine transaminase(ALT) \< 3 times the upper limit of normal, and alkaline phosphatase \< 5 times the upper limit of normal.~10. Adequate cardiac reserve with at least 45% of Left ventricular ejection fraction (LVEF) by echocardiogram.~11. Able to give informed consent.~12. Life expectancy of at least 12 weeks.~Exclusion Criteria:~1. Pregnant or breast feeding.~2. ECOG score ≧2~3. DFI \<12 months.~4. LVEF \< 45% by echocardiogram.~5. Uncontrolled medical problems.~6. Evidence of active acute or chronic infection.~7. Hepatic, renal, or bone marrow dysfunction as detailed above.~8. Concurrent malignancy or history of other malignancy within the last five years except as noted above.~9. Known severe hypersensitivity to Trastuzumab.~10. Patients were unable or unwilling to comply with program requirements.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Palliative chemotherapy (Type: ACTIVE_COMPARATOR): Chemotherapy combined with trastuzumab. Chemotherapy could use the following drugs such as capecitabine , Vinorelbine, or Gemcitabine.
- Palliative endocrine therapy (Type: EXPERIMENTAL): Endocrine therapy combined with trastuzumab. Endocrine therapy could use tamoxifen or aromatase inhibitors including anastrozole, letrozole, or exemestane.

Based on this trial design, predict the completion outcome and termination type (if applicable).